3 enrolling by invitation. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Enrolling by invitation 3 |
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INSIGHT-IBD Pragmatic Study Mirikizumab, Anti-TNF agents, anti-integrin antibodies - Ulcerative Colitis (UC), Crohn Disease (CD) | Phase 4 | Enrolling by invitation | Specialty Networks Research. | 400 | 2026-08-12 | 2026-10-29 |
| MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease PK-model to decide when to dose Vedolizumab and Ustekinumab - Inflammatory Bowel Diseases, Crohn Disease | Phase 4 | Enrolling by invitation | Odense University Hospital | 166 | 2026-01-23 | 2026-11-06 |
| De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease Infliximab, Adalimumab - Inflammatory Bowel Diseases, Crohn Disease | Phase 4 | Enrolling by invitation | University Medical Center Groningen | 148 | 2021-03-11 | 2025-01-06 |
Colitis, Ulcerative (3) · Crohn Disease (3) · Inflammatory Bowel Diseases (2)
Colonic Diseases (3) · Digestive System Diseases (3) · Gastroenteritis (3) · Gastrointestinal Diseases (3) · Intestinal Diseases (3) · Inflammatory Bowel Diseases (1)
Adalimumab (1) · CT-P13 (1) · Infliximab (1) · Interleukin-12 (1) · Interleukin-23 (1) · Ustekinumab (1) · mirikizumab (1)
Odense University Hospital (1) · Specialty Networks Research. (1) · University Medical Center Groningen (1)
Belgium (1) · Denmark (1) · Netherlands (1) · Spain (1) · United States (1)
Casey Chapman, MD (1) · Mark A Ainsworth, professor, DMSc (1) · Nicholas Lazarou, MPH, MBA (1) · Patrick F van Rheenen, MD PhD (1)